

**DCAT**

# TOP Industry NEWS

*BUSY WEEK? Here are the  
TOP INDUSTRY NEWS stories  
you might have missed, as  
selected by DCAT Editorial  
Director Patricia Van Arnum.*

## 1. [Sanofi To Invest \\$340 Million to Expand Biologics Manufacturing](#)

Sanofi plans to invest EUR 300 million (\$341 million) to expand its site in Geel, Belgium for biologics manufacturing. Updates to the existing facility, which will support the company's monoclonal antibody pipeline, will include the development of new laboratories focused on quality control and manufacturing sciences. [Read More](#)

## 2. [Novo Nordisk Plans \\$110 Million Investment in French Manufacturing Facilities](#)

Novo Nordisk plans to invest more than EUR 100 million (\$113 million) in production facilities at its site in Chartres, France. The new facilities will be built on Novo Nordisk's existing 31,000-square meter site in Chartres, which produces a range of the company's insulin products as well as FlexPen, an insulin injection device. [Read More](#)

## 3. [Novartis Updates Progress in Procurement and Manufacturing Initiatives](#)

Novartis outlined progress in its initiatives for improved operational efficiency, including cost savings in Procurement and manufacturing. The company reported gross savings of approximately \$500 million from productivity initiatives in the first quarter, which included \$300 million savings from Procurement. [Read More](#)

## 4. [AbbVie Signs Deal Worth Up to \\$685 Million for Immunology Drug Candidate](#)

AbbVie and argenx, a clinical-stage biopharmaceutical company developing treatments for cancer and severe autoimmune diseases based in Breda, the Netherlands, will collaborate to develop and commercialize ARGX-115. argenx' preclinical-stage human antibody program targeting the immuno-oncology target GARP, a protein believed to contribute to immuno-suppressive effects of T-cells, in a deal valued up to \$685 million. [Read More](#)

## 5. [AbbVie, CytomX Therapeutics Form \\$500 Million Drug Conjugate Pact](#)

AbbVie and CytomX Therapeutics have formed a collaboration, valued up to \$500 million, to co-develop and co-commercialize Probody Drug Conjugates against CD71, also known as transferrin receptor 1, which is expressed in solid and hematologic cancers. Probody therapeutics are designed to remain inactive until they are activated by proteases in the tumor microenvironment and seek to overcome limitations of conventional antibody-drug conjugates. [Read More](#)

## 6. [Daiichi Sankyo To Establish New US HQ in New Jersey](#)

Daiichi Sankyo, Inc., the US subsidiary of the Japanese pharmaceutical company, Daiichi Sankyo Company, Ltd., will establish a new US headquarters, co-locating its commercial and development divisions in Basking Ridge, New Jersey. The move is part of an ongoing effort to realize efficiencies and continue collaboration between the business segments. [Read More](#)

## 7. [GSK Expands Inhaler Capacity in the UK](#)

GlaxoSmithKline has opened a £56 million (\$81 million), 4,500-square meter manufacturing facility in Ware, Hertfordshire, the UK, to produce respiratory medicines delivered by the Ellipta multi-dose dry powder inhaler. It is the latest expansion for Ellipta manufacturing at Ware, with investment totaling

over £100 million (\$144 million) over the past five years. [Read More](#)

## 8. [Allergan Acquires Topokine Therapeutics](#)

Allergan has acquired Topokine Therapeutics, a privately held, clinical-stage biotechnology company focused on developing topical medicines for fat reduction, for an upfront payment of \$85 million and success-based development and sales milestones for XAF5, a topical agent in late-stage development for treating steatoblepharon, also known as under-eye bags. [Read More](#)

## 9. [Recipharm To Acquire Kemwell's CDMO Businesses in US, Sweden, and India](#)

Recipharm, a CDMO based in Jordbro, Sweden, has signed two separate agreements to acquire Kemwell's pharmaceutical CDMO businesses. The first deal involves Recipharm's acquisition of Kemwell's US and Swedish operations for \$160 million. The second deal involves Recipharm's acquisition of Kemwell's CDMO operations in India for \$120 million. The agreement also includes a right of first negotiation to acquire Kemwell's Indian biopharma business, which is not included in the deal. [Read More](#)

## 10. [Hanmi Science To Invest \\$200 Million To Expand Manufacturing, R&D](#)

Hanmi Science, the holding company of Hanmi Pharmaceutical, based in Seoul, Korea, plans to invest \$200 million until 2026 in China to build facilities for the production of chemical and biologic drugs and health supplements, as well as an R&D center for new drug development. [Read More](#)

### **\*\*Save the Date: DCAT Sharp Sourcing\*\***

Mark your calendar for **Tuesday, July 12** for **DCAT Sharp Sourcing**, the must-attend event for pharmaceutical companies, contract service providers and suppliers engaged in the pharmaceutical manufacturing value chain. This year's event will be held at the Hyatt Regency Hotel in New Brunswick, New Jersey and will feature solution-based practical insights from leading industry experts, specialized educational forums for buyers and suppliers, networking opportunities, and a special keynote speaker. Gain peer and customer insight on best practices and ways for optimizing your internal and external manufacturing and supply networks. Watch for announcements from DCAT for further details.

*The DCAT organization is happy to provide this service to its members each Friday.  
Have a great weekend!*

---

### **About Top Industry News**

The DCAT organization recognizes its members have minimal time to keep up with the continuous flow of news covering this dynamic industry. To help ensure our members never miss the most important stories impacting the global pharmaceutical manufacturing industry, we will deliver each Friday, the week's Top Industry News, as selected by DCAT Editorial Director Patricia Van Arnum.



The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.



One Union Street, Suite 208, Robbinsville, NJ 08691  
Local: +1.609.208.1888 · Toll Free: +1.800.640.DCAT(3228) · Fax: +1.609.208.0599

[www.dcat.org](http://www.dcat.org)

Drug, Chemical, & Associated Technologies Association, One Union Street,  
Suite 208, Robbinsville, NJ 08691

SafeUnsubscribe™ {recipient's email}

[Forward this email](#) | [Update Profile](#) | [About our service provider](#)

Sent by [dcatnews@dcat.org](mailto:dcatnews@dcat.org)